Insurers put squeeze on Biogen Alzheimer’s drug

Call it the first big shot across Biogen’s bow in what may become a multi-billion-dollar war in which the hopes of millions for a way to hold back the ravages of Alzheimer’s disease are colliding with the uncertain benefits of a new drug and the explosion of already sky-high health care costs its widespread use(...)

Read More »